Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Talus Bio logo — Gene regulator profiling in live cells for drug development

Talus Bio

Gene regulator profiling in live cells for drug development

Founded 2020 United States Seattle, United States 24 employees Grant Total: $14.31M Biotechnology, Health Care +1

General Information

Company Name Talus Bio
Founded Year 2020
Location United States Seattle, United States
Employees 24
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Talus Bio. To contact Talus Bio, visit talus.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Talus Bio compare?

A PDF of Talus Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Talus Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Talus Bio

Talus Bio is an early-stage biotechnology startup company focused on gene regulator profiling for drug development. The company spun out of University of Washington and Altius Institute for Biomedical Sciences in September 2020 and is based in Seattle, WA. Their venture-backed operations received a $4.30M grant investment on 18 August 2023 from the Andy Hill Cancer Research Endowment (CARE) Fund and the National Institutes of Health. Talus Bio's innovative platform allows for the measurement of a drug's ability to disrupt a gene regulator within its living cellular environment, providing insights into in-cell drug activity and specificity. Their approach simultaneously measures activity for approximately 1,000 gene regulators, offering comprehensive data in a single experiment. The company focuses on small-molecule drug development in oncology and aims to develop programs against previously undruggable gene regulators in cancers with poor standard of care. In addition to internal development programs, Talus Bio collaborates with pharma, biotech, and academic labs to advance their pipeline of gene regulator drugs. With a strong emphasis on data-enabled drug development, the company's platform combines innovative cell processing, high-sensitivity quantitative proteomics, and advanced downstream analytics to open up new opportunities in the field of gene regulation for drug discovery.

Business keywords: drug development, gene regulation, oncology, small-molecule drugs, cellular environment, proteomics, quantitative analysis, cancer treatment, drug discovery, pharmaceutical partnerships, biotech collaborations, data-enabled platform, cell processing, startup

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $4.30M 2
Andy Hill Cancer Research Endowment (CARE) Fund
Andy Hill Cancer Research Endowment (CARE) Fund, National Institutes of Health
18 Aug 2023
Grant $2.75M 1
National Institutes of Health
06 Jun 2022
Seed Round $7.00M 3
NFX North South Ventures Farvatn Venture
NFX, North South Ventures +1
06 Jun 2022
Seed Round Undisclosed 7
Reinforced Ventures Y Combinator Pioneer Fund
Reinforced Ventures, Y Combinator +5
21 Aug 2021
Grant $255.83K 1
National Science Foundation
National Science Foundation
21 Apr 2021

Talus Bio Alternatives & Competitors

View All Alternatives
Talus Bio vs
Tetralogic Pharmaceuticals
Tetralogic Pharmaceuticals

TetraLogic Pharmaceuticals (Nasdaq: TLOG) is a clinical-stage biopharmaceutical company focused on d...

Convertible Note
10 employees
Biotechnology, Health Care
Talus Bio vs
Kancera
Kancera Sweden

Kancera is developing a new class of drugs for treatment of inflammation and cancer

8 employees
Biotechnology, Health Care
Talus Bio vs
Astex Pharmaceuticals
Astex Pharmaceuticals United Kingdom

Committed to the fight against cancer and CNS disorders

136 employees
Biotechnology, Health Care
View all alternatives

FAQ About Talus Bio

Gene regulator profiling in live cells for drug development
Talus Bio was founded in 2020.
Talus Bio is headquartered in Seattle, United States.
Talus Bio operates in Biotechnology, Health Care and Health and Wellness. Its work centres on drug development, gene regulation, oncology and small-molecule drugs.
Talus Bio has approximately 24 employees.
Talus Bio has completed 5 funding rounds, raising a total of $14.31M. The latest funding stage is Grant.
Top alternatives and competitors to Talus Bio include Tetralogic Pharmaceuticals, Kancera, Astex Pharmaceuticals , MediMabBio, Advenchen Laboratories, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Talus Bio and Tetralogic Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Talus Bio, https://bouncewatch.com/company/talus-bio, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes